Sharemaestro Newsreel

Danica Pension Livsforsikringsaktieselskab Invests $12.14 Million in Amgen Inc. $AMGN

Danica Pension Livsforsikringsaktieselskab has acquired a new stake in Amgen Inc. (NASDAQ:AMGN), purchasing 34,491 shares valued at approximately $12.14 million in the first quarter. This comes as Amgen reported strong Q1 earnings, surpassing analyst estimates, and received revised price targets from several Wall Street …

Gilead (GILD) Stock Could Still Trade At A Discount Following Its 127% Run

Gilead Sciences (GILD) has seen a significant 126.8% return over the past five years, yet its stock remains undervalued according to various metrics and valuation models. Despite its strong performance, particularly in its HIV portfolio, and a P/E ratio close to the biotech industry …

Pfizer (PFE) Stock Seems Fairly Priced As Oncology Approvals Build

Pfizer's stock, though down over five years, appears fairly priced based on current valuation checks and a P/E ratio of 18.9x, which aligns closely with Simply Wall St's fair P/E of 19.7x. The company's recent oncology and weight-loss drug approvals are balanced by patent …

ORGANON CANADA ANNOUNCES THE APPOINTMENT OF DOMINIC BÉGIN AS PRESIDENT AND MANAGING DIRECTOR

Organon Canada has announced the appointment of Dominic Bégin as its new President and Managing Director. Bégin, a founding member of Organon Canada's leadership team, will focus on expanding the company's presence, driving growth, and increasing patient access to medicines, including biosimilars. He brings …

ABN Amro Investment Solutions Cuts Holdings in Amgen Inc. $AMGN

ABN Amro Investment Solutions reduced its stake in Amgen Inc. by 18.1% in the first quarter, selling 12,829 shares and holding 58,173 shares valued at $20.47 million. Several other institutional investors also adjusted their holdings, with some increasing stakes while ABN Amro decreased its …

Novartis: The Buy Thesis Is Back (Rating Upgrade)

Amarin (AMRN) Projected to Release Earnings on Wednesday

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

$Eli Lilly and Co (LLY.US)$

This article features a brief community post by user "TACO Tariff Sheriff" on the Moomoo platform about Eli Lilly and Co (LLY.US). The post includes a disclaimer that the community content is for educational purposes only. It also showcases various market insights and thematic …

Return on assets % of Merck & Co., Inc. – BCS:MRK1

This article provides financial data for Merck & Co., Inc. (BCS:MRK1) focusing on its Return on Assets percentage. It is a data page from TradingView, indicating market status, and offers various financial metrics and community tools related to the company.

Amgen (AMGN) Clears An Enbrel Overhang, Is The Stock Fully Priced?

A recent court decision blocking Colorado's planned 70% price cap on Enbrel has removed a regulatory overhang for Amgen (AMGN). While a community narrative suggests Amgen is slightly overvalued at $359.98, Simply Wall St's DCF model indicates the stock is materially undervalued with an …

Novartis Number of Employees 2026 | Employee Count & Headcount Data

Novartis AG had approximately 75,497 employees worldwide as of March 2026, representing a 1.2% decline from 2023. The company is actively hiring, with 2,864 job postings in 2026, though hiring velocity has slowed. The largest employee concentrations are in the United States, India, and …

Amgen (AMGN) Stock Looks Reasonable On Earnings While Cash Flow Stays Strong

Amgen's stock has shown a 75.2% return over five years, with its current valuation presenting a mixed picture. A Discounted Cash Flow (DCF) analysis suggests a significant undervaluation of 46.5%, estimating an intrinsic value of $685 per share, based on strong future cash flow …

Earnings Preview: AstraZeneca to Report Financial Results on July 27

This article provides an earnings preview for AstraZeneca (AZN), stating that the pharmaceutical giant is scheduled to report its financial results on July 27. Investors will be closely watching for details on the company's performance, including revenue growth from new drug launches and overall …

[AIDS 2026] [Press release] Gilead & Merck: Investigational once-weekly oral HIV treatment regimen of islatravir and lenacapavir maintained virological suppression in adults with HIV who switched antiretroviral therapy

Gilead Sciences and Merck will present detailed outcomes from their Phase 3 ISLEND-1 and ISLEND-2 trials at AIDS 2026. The investigational once-weekly oral HIV treatment regimen of islatravir 2 mg/lenacapavir 300 mg (ISL/LEN) demonstrated effectiveness in virally suppressed adults with HIV who switched from …

How Investors May Respond To AbbVie (ABBV) Securing EU Approval For Short-Acting Boey Aesthetic Toxin

AbbVie (ABBV) recently secured EU approval for Boey, a short-acting aesthetic toxin for treating glabellar lines, which broadens its aesthetics portfolio. While this approval adds incremental support, the primary drivers for AbbVie's investment narrative remain its immunology and neuroscience engines, balancing patent losses and …

Johnson & Johnson EVP Broadhurst sells $5.79m in stock

Vanessa Broadhurst, EVP of Global Corporate Affairs at Johnson & Johnson, sold 23,054 shares of company stock for approximately $5.79 million. Simultaneously, she acquired the same number of shares through the exercise of employee stock options totaling $3.01 million. These transactions have resulted in …

Novartis AG 2Q Net Pft $3.3B

Novartis AG announced its second-quarter net profit of $3.3 billion. This figure indicates the company's financial performance during that period.

Ozempic-maker Novo Nordisk accuses rival Eli Lilly of false advertising

Novo Nordisk, the maker of Ozempic and Wegovy, has filed a lawsuit against rival Eli Lilly, accusing it of false advertising. Novo Nordisk claims Eli Lilly's ad campaigns for Mounjaro and Zepbound misleadingly present their drugs as superior by comparing their highest doses to …

EBIT per share of AbbVie, Inc. – BCS:ABBVCL1

This article provides financial information for AbbVie, Inc. under the ticker ABBVCL1 on the Santiago Stock Exchange, specifically focusing on its EBIT per share. It indicates that the market is currently closed with no trades. The content is primarily a data page from TradingView, …

Novo Nordisk (CPSE:NOVO B) Stock Looks Reasonable On Earnings While Returns Stay Weak

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk stock has had a tough stretch over the past few years, yet current valuation checks suggest the market may now be pricing it …

AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know

AbbVie (ABBV) stock closed up 1.11% in its latest trading session, outperforming the S&P 500 and the Medical sector over the past month. The company is set to release its Q2 earnings on July 31, 2026, with analysts predicting significant growth in EPS and …

Bristol Myers Squibb (BMY) Opens 427,000 Square Foot San Diego Hub For AI Drug Discovery

Bristol Myers Squibb (BMY) has opened a significant 427,000 square foot R&D hub in San Diego, integrating NVIDIA-powered AI infrastructure to accelerate drug discovery. This initiative aims to enhance the speed and efficiency of its oncology, cardiovascular, and immunology programs, potentially offsetting patent expiries …

Press Release: Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Gilead Sciences announced its plans to release second-quarter 2026 financial results on Tuesday, August 4, 2026. The company will host a webcast and conference call to discuss these results later that day. Interested parties can access the webcast and accompanying slides on the company's …

ETFs Investing in Gilead Sciences, Inc. Stocks

This article lists various ETFs that include Gilead Sciences, Inc. (GILD0) stocks in their portfolios. The ETFs are sorted by market value and provide details such as weight, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, and 3-year NAV total …

Non-controlling/minority interest of Merck & Co., Inc. – BCS:MRKCL1

This page provides financial information for Merck & Co., Inc. (MRKCL1) traded on the Santiago Stock Exchange, specifically focusing on its non-controlling/minority interest. It notes that the market is currently closed with no trades. The content primarily displays navigation and boilerplate information without specific …

Top Research Reports for Eli Lilly, Costco & Morgan Stanley

Tuesday, July 21, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Costco Wholesale Corp. (COST) and Morgan Stanley (MS), as well …

AI is helping speed up the timelines of drug discovery, Novartis CEO says

Novartis stock (NVS) gets a lift higher on Tuesday after topping second quarter earnings estimates. Novartis CEO Vas Narasimhan sits down with Julie Hyman to talk more about the pharma giant's research into utilizing AI to aid in new drug discovery. Video Transcript 00:00 …

Amgen Settles Investor Suit Over Tax Liability for $74 Million

Amgen Inc. has agreed to a $74 million settlement in an investor lawsuit. The suit alleged that the pharmaceutical company delayed informing investors about potential tax liabilities totaling $10.7 billion with the IRS. The proposed settlement covers investors who purchased Amgen stock between July …

Enterprise value of AbbVie, Inc. – BCS:ABBV0

This article from TradingView is a placeholder page for the enterprise value of AbbVie, Inc. (BCS:ABBV0) on the Santiago Stock Exchange. It provides market data, financial links, and community features, but lacks specific valuation data. The page indicates that the market is closed and …

AbbVie Stock Zigs When The Market Zags

AbbVie (ABBV) stock has shown a counter-cyclical pattern, rising even as the broader market declines, with a low correlation to the S&P 500. This is attributed to its strong business fundamentals, including growth in immunology drugs like Skyrizi and Rinvoq, and recent positive Phase …

Novo sues Lilly, claiming misleading ads in weight-loss drug battle

View Comments

Novo Nordisk sues Eli Lilly, alleging the company's GLP-1 ads are 'deliberately false'

Novo Nordisk has filed a lawsuit against Eli Lilly, claiming that the latter's GLP-1 weight-loss drug ads for Zepbound are "deliberately false." Novo Nordisk alleges that Eli Lilly's advertisements for Zepbound deceptively suggest superior weight loss compared to Novo Nordisk's Wegovy, based on outdated …

Gilead and Merck report weekly HIV trial results

Gilead Sciences (NASDAQ:GILD) and Merck (NYSE:MRK) have announced successful 48-week results for their once-weekly oral HIV regimen in two Phase 3 trials, ISLEND-1 and ISLEND-2. The trials showed that the treatment maintained viral suppression with a low percentage of patients above the viral-load threshold, …

Johnson & Johnson (JNJ) Stock Looks Fairly Valued With Cash Flow Upside

Johnson & Johnson (JNJ) stock shows a mixed valuation picture, with a discounted cash flow (DCF) model suggesting it is 34.1% undervalued, while its P/E ratio indicates fair valuation close to its modeled fair P/E and slightly above industry average. The company's future growth …

Total liabilities & shareholders' equities of Biogen Inc. – BCS:BIIB1

The article provides financial information for Biogen Inc. (BCS:BIIB1) on the Santiago Stock Exchange, specifically focusing on its total liabilities and shareholders' equities. It appears to be a financial data page from TradingView, offering an overview of the company's financial metrics. The page is …